BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bischof M, Weber K, Blatter J, Wannenmacher M, Latz D. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. International Journal of Radiation Oncology*Biology*Physics 2002;52:1381-8. [DOI: 10.1016/s0360-3016(01)02794-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Wouters A, Pauwels B, Lardon F, Pattyn GG, Lambrechts HA, Baay M, Meijnders P, Vermorken JB. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. BMC Cancer 2010;10:441. [PMID: 20723210 DOI: 10.1186/1471-2407-10-441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
2 Müller C, Schibli R. Prospects in folate receptor-targeted radionuclide therapy. Front Oncol 2013;3:249. [PMID: 24069581 DOI: 10.3389/fonc.2013.00249] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
3 Choy H, Schwartzberg LS, Dakhil SR, Garon EB, Gerber DE, Choksi JK, Govindan R, Peng G, Koustenis A, Treat J. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol. 2013;8:1308-1316. [PMID: 23981966 DOI: 10.1097/jto.0b013e3182a02546] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Ann Oncol 2011;22:2482-8. [PMID: 21363880 DOI: 10.1093/annonc/mdr002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
5 Shen X, Denittis A, Werner-Wasik M, Axelrod R, Gilman P, Meyer T, Treat J, Curran WJ, Machtay M. Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma. Radiat Oncol 2011;6:17. [PMID: 21324160 DOI: 10.1186/1748-717X-6-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Dorn P, Tièche CC, Peng RW, Froment L, Schmid RA, Marti TM. Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells. Cancer Cell Int 2016;16:66. [PMID: 27594806 DOI: 10.1186/s12935-016-0346-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Müller C, Guzik P, Siwowska K, Cohrs S, Schmid RM, Schibli R. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates. Molecules 2018;23:E1465. [PMID: 29914162 DOI: 10.3390/molecules23061465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kaira K, Ono A, Kamide Y, Sunaga N, Koga Y, Saitoh JI, Shirai K, Ebara T, Hisada T, Ishizuka T. Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non-small-cell lung cancer. J Radiat Res 2019;60:228-33. [PMID: 30496584 DOI: 10.1093/jrr/rry058] [Reference Citation Analysis]
9 Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Ann Oncol 2016;27:1594-600. [PMID: 27177865 DOI: 10.1093/annonc/mdw204] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
10 Tamiya A, Morimoto M, Fukuda S, Naoki Y, Ibe T, Okishio K, Goto H, Yoshii A, Kita T, Nogami N, Fujita Y, Atagi S. A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Invest New Drugs 2018;36:667-73. [PMID: 29572782 DOI: 10.1007/s10637-018-0587-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Miller DS, Blessing JA, Ramondetta LM, Pham HQ, Tewari KS, Landrum LM, Brown J, Mannel RS. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol 2014;32:2744-9. [PMID: 25071133 DOI: 10.1200/JCO.2013.54.7448] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
12 Ai X, Qiu B, Zhou Y, Li S, Li Q, Huan J, Li J, Hu N, Chen N, Liu F, Wang D, Chu C, Wang B, Chen L, Jiang H, Huang S, Huang X, Bi N, Liu H. Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: Clinical outcomes and theoretical results from an extended LQ and TCP model. Radiother Oncol 2021;167:34-41. [PMID: 34890734 DOI: 10.1016/j.radonc.2021.11.033] [Reference Citation Analysis]
13 Fu C, Li B, Guo L, Li H, Huang W, Gong H, Sun M, Wang Z, Zhou T, Liu C. Phase II study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed and cisplatin for locally advanced oesophageal squamous cell carcinoma. Br J Radiol 2014;87:20130656. [PMID: 24666012 DOI: 10.1259/bjr.20130656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]